Testing the ConvitVax vaccine for metastatic breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new vaccine called ConvitVax for people with metastatic breast cancer that has continued to grow after standard treatments. The goal is to see if the vaccine is safe and helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You must have breast cancer that has spread or cannot be removed by surgery or radiation.
- You must have a measurable tumor that is at least 1 cm by 1 cm.
- You cannot have had certain cancer treatments within weeks before starting the trial (your doctor will check the timing).
- You must not be pregnant or breastfeeding and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a vaccine that targets HER2 protein on cancer cells. It is for people with advanced breast or esophageal cancer whose tumors have certain markers. The vaccine may help your immune system fight the cancer.
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
This trial tests a vaccine (MV-s-NAP) that is injected directly into a tumor to stimulate your immune system against breast cancer. It is for people with metastatic breast cancer that has spread despite prior treatments.
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.